The $125,000-per-injection price of its new rare disease drug Spinraza has now kept it from getting coverage and turning in $203 million in sales for its…

AbbVie lost the first jury trial in a series of bellwether AndroGel cases, to the tune of $150 million in damages.

GlaxoSmithKline employees will be measured on their "courage" as new CEO Emma Walmsley impresses her own style on employees.

A second Remicade biosimilar hit the U.S. market to take a larger slash at pricing.

A long patent battle against Momenta and Sandoz has ended in Amphastar’s favor, freeing the small drugmaker from the threat of almost $1B in damages.

More uncertainty has roiled Teva, as the company indicated it would eliminate up to 350 production workers in Israel.

A new report sets out pharma's U.S. pricing problem, and topping it off is the growing cost of access: $1,100 per capita.

GlaxoSmithKline hopes to get its new Benlysta formula under lupus patients’ skin—literally.

With early HIV vaccine results announced Monday, Johnson & Johnson and its partners hope they might have a winner.